Study on metabolis and regulatory mechanism of Diyu Shengbai Tablets in renal transplant patients based on metabonomics technique

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000032909

Enrollment

Unknown

Registered

2020-05-15

Start date

2021-09-06

Completion date

Unknown

Last updated

2022-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ischemia - reperfusion injury of transplant kidney

Interventions

Diyu Shengbai Pian :Oral Diyu Shengbai Pian

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Trenal transplant patients administrated Diyu Shengbai Pian; 2. Patients voluntarily participate in the trial and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Combined with severe liver dysfunction; 2. Blood transfusion and plasma exchange; 3. Poor compliance; 4. Participated in other clinical trials.

Design outcomes

Primary

Measure	Time frame
Hematology and urine metabolomics;	—

Countries

China

Contacts

Public ContactZhou Benhong

Renmin Hospital of Wuhan University

benhongzh@whu.edu.cn+86 13808664512

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026